Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DBV TECHNOLOGIES SA. We currently have 2 research reports from 1 professional analysts.
|22Mar17 21:30||GNW||DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F|
|15Mar17 06:30||GNW||DBV Technologies Reports Full Year 2016 Financial Results|
|10Mar17 06:30||GNW||DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children|
|05Mar17 20:45||GNW||DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children|
|01Mar17 06:30||GNW||DBV Technologies to Attend Upcoming Investor Conferences|
|20Feb17 06:30||GNW||DBV Technologies Reports December 31, 2016 Cash Position|
|10Feb17 21:30||GNW||DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®|
Frequency of research reports
Research reports on
DBV TECHNOLOGIES SA
DBV TECHNOLOGIES SA
Enlarged Phase III PEPITES study starts
09 Dec 15
DBV has now started the Phase III Viaskin Peanut trial (PEPITES), which has been enlarged to meet patient and investigator demand, a positive sign for future potential uptake. The Phase II Viaskin Milk trial (SMILEE) has also started as a potential treatment for EoE, a food-allergy related disease. The EoE trial broadens DBV’s focus beyond traditional food allergy, which includes peanut, cow’s milk and hen’s egg allergy.
Further VIPES responder analyses at EAACI
11 Jun 15
Additional data from DBV’s Phase IIb VIPES trial have been presented at EAACI. A further post hoc analysis applying more rigorous efficacy criteria reinforces the strength of the existing data, in our view. DBV also hosted a well-attended physician symposium, highlighting interest in DBV’s Viaskin products and helping to raise broader awareness, both key for a successful launch. Our valuation is largely unchanged at €1,201m.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017